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24 Oral PresentationsSCT. Median whole blood donor chimerism on days 30, 60, 100, and
180 was 95%(9–100), 90%(61–99), 90%(60–99), and 91%(88–98),
respectively. Median CD71 chimerism on days 30, 60, 100, and
180 was 98%(17–99), 88%(1–99), 90%(71–99), and 92%(80–96), re-
spectively. Hb electrophoresis demonstrated median %HbS levels of
1.160.1, 060.1, and 1.060.1 on days 30, 60, and 100 respectively.
Of evaluable patients, Grades II-IV acute GVHD was seen in
4/13(30.7%) patients and chronic extensive GVHD was seen in 1/
9 (11.1%) patients. Three patients developed CMV pre-engraftment
(CMV pneumonitis (n 5 2), CMV viremia (n 5 1)) and one devel-
oped CMV viremia post engraftment. OS is 100% (longest follow
up 1491 days). In summary, RIC and AlloSCT in patients with
SCD using both related and unrelated donors has been shown to
be well tolerated and effective in inducing a high degree of
sustained mixed donor chimerism.57
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Genetic modification of T cells to express a chimeric antigen re-
ceptor (CAR) is a promising therapy for the treatment of malignan-
cies and we have implemented a clinical trial infusing T cells which
express CAR after electro-transfer of DNA plasmid vector. However,
generating CAR1 T cells for diseases that are rapidly progressing,
such as relapsed pediatric B-lineage acute lymphoblastic leukemia
(B-ALL) after allogeneic hematopoietic stem-cell transplantation
(HSCT) is challenging. To meet this challenge we have combined
bioengineering with immunotherapy to develop a new platform tech-
nology for gene transfer of CAR into T cells. This approach side-
steps the problem associated with conventional viral and non-viral
methods for gene transfer that rely on integrating expression vectors
which are typically laborious (sometimes taking weeks of cell-culture
to generate clinically-significant cell doses) and expensive. What is
needed, and is provided here, is a cost-efficient approach to the
genetic transfer of large numbers of minimally manipulated T cells
that can be rapidly modified ex vivo and immediately infused for in
vivo therapy. We have fabricated and tested a series of high through-
put micro-electroporation devices (HitMeds). The initial multi-
electrode HitMed was designed to investigate the electroporation pa-
rameters in a channel with single-cell flow dynamics. Subsequently,
a ‘‘wafer-type’’ HitMed was developed to handle a large number of
T cells in short time. The area of the electrodes of wafer-HitMed is
3,600 mm2 (commercial cuvette: 144 mm2) with a gap, initially set
at 400 mm, but which can be easily changed to enable large numbers
of T cells to be synchronously electroporated. We have adapted the
wafer-HitMed to the electro-transfer of mRNA to avoid genotoxicity
associated with integration. The data in Table 1 demonstrates that
a CD19-specific CAR coded from introduced mRNA is efficiently
electro-transferred into T cells. The expression of CAR transgene
was 80% 24 hours after electroporation as determined by flow cytom-
etry analysis. We recognize that the CAR expression is transient, but
this can be compensated through repeated infusions of the CAR1 T
cells. We foresee the implementation of micro-electroporators to
generate CAR1 T cells for immediate infusion to achieve B-ALL
disease control. As needed, these initial infusions may be followed by
adoptive immunotherapy of T cells with stable CAR expression for
disease eradiation and prevention.Expression of CAR and GFP (%)
Cuvette Cuvette HitMed HitMedCAR GFP CAR GFP
DNA 31.05 44.04 23.95 36.74
mRNA 78.39 82.48 80.02 90.6758
ADENOVIRUS DNA POSITIVITY IN NASOPHARYNGEAL FLUID PRECEED-
ING HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A VERY STRONG
PREDICTOR FOR ADENOVIRUSREACTIVATION IN PEDIATRIC PATIENTS
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Objective: After paediatric haematopoietic stem cell transplanta-
tion (HSCT) adenovirus (HAdV) infection is a severe complication
with high morbidity and mortality rate. By intensive surveillance
patients at high risk for developing HAdV disease can early be iden-
tified in order to start preemptive therapy with antiviral medication
in an early stage.
Methods: In a prospective study, we determined the predictive
value of HAdV DNA positivity in nasopharyngeal fluid preceding
HSCT to identify patients at risk for a plasma HAdV reactivation af-
ter HSCT. We weekly monitored Adenovirus DNA loads in plasma
after HSCT. HAdV reactivation was defined as plasma viral DNA
load .1000cp/mL. Secondly, the association between plasma
HAdV reactivation and alloreactive disease (Graft-versus-Host
disease and/or idiopathic pulmonary syndrome) was analyzed, using
Cox proportional hazard models.
Results: A total of 62 patients were included: 37 (60%) recipients
received bone marrow (17/37, 46%, matched family donor) or
unrelated peripheral blood stem cells while 25 (40%) recipients re-
ceived unrelated cord blood stem cells. 42/62 (68%) recipients re-
ceived HLA-matched stem cells (for BM/PBSC high resolution
typing, for CB intermediate: HLA-A and B on low and HLA-DR
on high resolution). All patients received myeloablative conditioning
and standardized Graft-versus-host disease prophylaxis. The median
follow-up time was 47 (5–150) weeks. Prior to HSCT, HAdV DNA
could be detected in nasopharyngeal fluid of 8/62 patients (13%). In
all these patients (100%), plasma HAdV reactivation occurred
during isolated hospitalization at a median time of 12.5 days (range
5–72 days) after HSCT. Additionally, 11 (18%) patients developed
plasma HAdV reactivation at a median time of 40 (14–160) days after
HSCT. In multivariate analysis HAdV DNA positivity in nasopha-
ryngeal fluid was the only significant predictor for plasma HAdV
reactivation after HSCT (HR 9.7; 95%CI 3.4–27.4; p 5 0.000).
Plasma HAdV reactivation was a predictor for allo-reactive disease
(HR 2.6; 95% CI 1.2–5.4; p 5 0.013).
Conclusions: HAdV positivity in nasopharyngeal fluid pre-
HSCT is a very strong predictor for the development of plasma
HAdV reactivation after HSCT. Prevention or early pre-emptive
treatment with antiviral therapy might contribute to prevent
HAdV disease and / or HSCT associated problems after HSCT.59
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UCBT offers a cure for thalassemia and has advantages as a stem
cell source because of the less stringent requirements for an HLA
match between donors and recipients. Previous reports of UCBT
for thalassemia have yielded transplant related mortality (TRM) that
appeared high. It is known that pre-freeze total nucleated cell
(TNC) dose is critical for UCBT. With strategies that maximize
TNC dose – using non-red cell reduced but plasma depleted (PD)
CB, no post-thaw wash (NW), and double cord transplantation
(DCT) when necessary – we have achieved promising results with
UCBT in young patients with transfusion-dependent b-thalassemia.
Between 10/2003 and 5/2008, 39 CB products were infused after
Bu/Cy/ATG myeloablation into 30 pediatric thalassemia major pa-
tients (9 DCT) using NW PD CB exclusively. Patient status: 21 Pe-
saro class-1, 8 class-2, and 2 unknown. Median age was 5 years
(range 1–14 years) with a median weight of 18 kg (range 11–37 kg).
The data was audited by the transplant center (TC) and on-site by
Oral Presentations 25CIBMTR (98.5% accuracy for Chang Gung). Median pre-freeze
TNC cell dose was 10.9107/kg, and median pre-freeze CD341
cell dose was 4.0105/kg. The number of CB products HLA ABDR
matched were 4, 11, and 24 for 6/6, 5/6, and 4/6 or fewer matches.
No significant adverse events were observed during infusion despite
major ABO incompatibility in some cases and forgoing post-thaw
wash. Cumulative incidences of donor-derived (chimerism confirmed)
neutrophil (ANC500), platelet 20K and 50K (plt 20K & 50K) engraft-
ment were 96611%, 92611% and 92612%, and median times to
ANC500, plt 20K and 50K engraftment were 17.5 days (range 11–
26), 49.5 days (range 28–135) and 63.5 days (range 35–203), respec-
tively. Acute GvHD was manageable and occurred in 61611%
(Grade II-IV), and extensive chronic GvHD occurred in only
464% of the patients. Five patients expired including 1 death prior
to day 110 due to traumatic head injury. 100-day and 1-year trans-
plant related mortality were 1065% and 1366%. Overall survival
at 1 and 3 years were 8766% and 8268%, while thalassemia-free sur-
vival at 1 and 3 years were 8567% and 7869%. Mean and median fol-
low up times were 24 and 16 months respectively (range 0.3–58
months) as of August 2008. To our knowledge, this is the largest sin-
gle-institutional UCBT series for thalassemia, and shows the favor-
able clinical results that are attainable when TNC dose is optimized
with PD CBU, no post-thaw wash and DCT when necessary.
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TREOSULFAN IN CONDITIONING REGIMENS IN CHILDREN WITH
NON-MALIGNANT DISORDERS, INCLUDING APLASTIC ANAEMIA-HIGH
RATE OF STABLE ENGRAFTMENT AND LOW TRANSPLANT-RELATED
MORTALITY
Kalwak, K., Owoc-Lempach, J., Gorczynska, E., Porwolik, J.,
Ussowicz, M., Musial, J., Wojcik, D., Pazdzior, D., Skarzynska, M.,
Dyla, A., Chybicka, A. Wroclaw Medical University, Wroclaw, Poland
Treosulfan is an immuno-suppressive and myeloablative alkylat-
ing agent that has been introduced as a conditioning agent in hema-
topoietic stem cell transplantation (HSCT), mostly in adults with
malignancies. Recently published UK study on 32 children with
non- malignant disease showed excellent engraftment with reduced
regimen- related toxicity. We report the use of treosulfan in 26
children (median age 8.2, range 0.4–17.8; SAA n5 14, inborn errors
n5 12, incl X-ALD n5 4, SCID n5 5, CGD n5 2 and Griscelli S.
n5 1) who underwent HSCT for non- malignant disease within last
five years. Patients received a total treosulfan dose of 30 g/m2 in SAA
pts with the maximum dose of 36 or 42 g/m2 in other pts. Patients
underwent matched sibling donor HSCT (n 5 5), matched or mis-
matched unrelated donor HSCT (n 5 18) or haploidentical T-cell
depleted PBSCT (n 5 3). All pts with vSAA received a unified
protocol incl. treosulfan 30 g/m2, CY 200 mg/kg and rabbit ATG.
The rationale for the use of treosulfan were: a/ risk of rejection in
heavily pretransfused SAA patients (treosulfan added to standard
CY); b/ the risk of inflammatory flare after busulfan (Bu) -containing
regimen in CGD, GS (HLH); c/ graft rejection after RIC (FluMel-
Campath) in CGD; d/ VOD risk after Bu-containing regimen in
v.small children with SCID and e/ risk of neurotoxicity and inflam-
matory flare after Bu-containing regimens in pts with X-ALD.
Median follow-up of SAA pts was 3.2 years and 1.7 years of others.
Severe mucositis was noted in only two pts (8%) with SAA. One pa-
tient with SAA (4%) died early due to renal insufficiency. Other 4 pts
with SAA died due to sepsis, TTP complicating GvHD and CLS. In
the inborn errors group 11 out of 12 pts (92%) remain alive with sta-
ble allogeneic (in 80% of pts) or mixed chimerism, in good clinical
status except for one SCID patient with BCG-itis flare posttrans-
plant. One patient with SCID died due to pneumonia. The above
presented results seem to be particularly promising considering the
majority of alternative transplants in the series (81% of either mis-matched or matched MUD or haploidentical T-cell depleted
PBSCT). In conclusion: treosulfan-based conditioning regimens
are associated with excellent engraftment and reduced regimen-re-
lated toxicity in children with SAA and especially in children with
non- malignant disease who are at high risk for both regimen-related
toxicity and graft failure. Treosulfan is worth special consideration in
children with HLH, CGD or ALD.61
FAVORABLE OUTCOMES IN PATIENTS WITH MALIGNANT INFANTILE
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Malignant infantile osteopetrosis (MIOP) is a rare autosomal re-
cessive hereditary disorder characterized by dysfunctional osteo-
clasts leading to distinctive facial features, hepatosplenomegaly,
and bone marrow failure. The only cure is HSCT, yet most do not
have a matched sibling donor. Time needed to identify a matched
unrelated donor may permit disease progression and extensive mar-
row fibrosis. Thus, alternative donors are to be considered. From
September 2004 to March 2008, we treated 5 consecutive MIOP pa-
tients (pts) using mismatched family member donors (4 were male)
on an IRB-approved prospective clinical trial designed to describe
outcomes and bone remodeling through 1 year after HSCT. The
median age at HSCT was 0.7 years (y) (range, 0.5–1.2 y). Each pt re-
ceived a reduced intensity preparative regimen of melphalan
(140mg/m2), fludarabine (200mg/m2), thiotepa (10mg/kg), and 27
days of OKT3. G-CSF mobilized PBSC grafts were CD3-depleted
using the CliniMACS selection system; no T-cell add-back was per-
formed. GVHD prophylaxis consisted of cyclosporine. Post-pro-
cessing, grafts contained a median of 32.1  106 CD341 cells/kg
(range, 27.9–68.6  106/kg) and 6.4  104 CD31 cells/kg (range,
3.1–15.5  104/kg). Neutrophil and platelet engraftment occurred
in all at a median time of 16 days (range, 12–18 days) and 67 days
(range, 15–93 days) after HSCT. Donor chimerism is 100% by
VNTR analysis in surviving pts. No pts had Grade 3–4 acute
GVHD; 2 developed Grade 2 skin acute GVHD. Chronic
GVHD, limited to skin in 1 patient, resolved in 7 months. One pt
had mild VOD and 2 required prolonged intubation for respiratory
failure. 1 pt required a CD341 boost and a T-lymphocyte boost for
poor graft function and eventually died of secondary graft failure and
CMV pneumonitis. The other 4 are alive and well at a median of 758
days after HSCT (range, 206–1467 days), all with a Lansky score of
100 at last visit. Bone mineral density was evaluated by computed to-
mography in pts at specific time points (Table1). Hearing has been
preserved in all 4 pts. Though vision is compromised, the older 2 sur-
vivors are able to discern colors without difficulty. MIOP pts under-
going haploidentical HSCT with a reduced intensity regimen
experience rapid hematopoietic engraftment, treatable toxicity, and
bone remodeling, resulting in favorable outcomes and indicating
that this treatment plan is a feasible option for this pt cohort who
lack a matched sibling donor and require rapid HSCT.
Quantitative computed tomography (qCT) results of MIOP
patients at specific time points before and after HSCT
Pre-HSCT 2 month 4 month 6 month 9 month 12 monthMedian qCT
Z-score26.33 26.55 21.41 17.32 8.28 6.99Range 20.24-
32.5724.70-
27.7515.99-
22.7113.98-
17.337.80-
13.203.25-10.72% change
from
baselineN/A [ 0.8% Y 18.7% Y 34% Y 68.6% Y 73.4%MIOP: malignant infantile osteopetrosis; HSCT: hematopoietic stem cell
transplantation; qCT: quantitative computed tomography; N/A: not ap-
plicable.
